Table 1 General characteristics of the patients
Molnupiravir (N=69) | mAbs (N=135) | Nirmatrelvir/Ritonavir (N=166) | Remdesivir (N=58) | p-value | |
|---|---|---|---|---|---|
Days of negativization | |||||
median [Q1, Q3] | 9.00 [7.00, 12.0] | 11.0 [7.00, 15.0] | 8.00 [7.00, 12.0] | 9.00 [7.00, 12.8] | 0.014 |
min-max | 4.00-26.0 | 4.00-44.0 | 4.00-42.0 | 4.00-38.0 | |
Age | |||||
median [Q1, Q3] | 79.0 [61.0, 84.0] | 61.0 [50.5, 73.0] | 64.0 [53.3, 77.0] | 65.5 [55.0, 73.8] | <0.001 |
min-max | 40.0-90.0 | 24.0-94.0 | 23.0-95.0 | 26.0-88.0 | |
Sex | |||||
0 | 30 (43.5%) | 62 (45.9%) | 83 (50.0%) | 26 (44.8%) | 0.773 |
1Male sex 111 | 39 (56.5%) | 73 (54.1%) | 83 (50.0%) | 32 (55.2%) | |
Anti-SARS-CoV-2 vaccination | |||||
No | 4 (5.8%) | 23 (17.0%) | 9 (5.4%) | 2 (3.4%) | <0.001 |
Yes | 65 (94.2%) | 112 (83.0%) | 157 (94.6%) | 56 (96.6%) | |
Number of vaccination doses | |||||
median [Q1, Q3] | 3.00 [3.00, 3.00] | 2.00 [2.00, 3.00] | 3.00 [3.00, 3.00] | 3.00 [3.00, 3.00] | <0.001 |
min-max | 0-5.00 | 0-4.00 | 0-4.00 | 0-4.00 | |
Virus variant | |||||
BA1 | 7 (10.1%) | 44 (32.6%) | 7 (4.2%) | 15 (25.9%) | <0.001 |
BA2, BN, XBB, OM4 | 13 (18.8%) | 23 (17.0%) | 55 (33.1%) | 11 (19.0%) | |
BA3, BA4, BA5, BE, BQ, BF | 22 (31.9%) | 1 (0.7%) | 45 (27.1%) | 6 (10.3%) | |
Delta | 3 (4.3%) | 34 (25.2%) | 1 (0.6%) | 2 (3.4%) | |
NA | 24 (34.8%) | 33 (24.4%) | 58 (34.9%) | 24 (41.4%) | |
Chronic kidney disease | |||||
No | 57 (82.6%) | 120 (88.9%) | 155 (93.4%) | 52 (89.7%) | 0.099 |
Yes | 12 (17.4%) | 15 (11.1%) | 11 (6.6%) | 6 (10.3%) | |
Cardiovascular disease | |||||
No | 13 (18.8%) | 73 (54.1%) | 90 (54.2%) | 22 (37.9%) | <0.001 |
Yes | 56 (81.2%) | 62 (45.9%) | 76 (45.8%) | 36 (62.1%) | |
Oncological disease | |||||
No | 59 (85.5%) | 111 (82.2%) | 138 (83.1%) | 48 (82.8%) | 0.948 |
Yes | 10 (14.5%) | 24 (17.8%) | 28 (16.9%) | 10 (17.2%) | |
COPD | |||||
No | 54 (78.3%) | 115 (85.2%) | 129 (77.7%) | 41 (70.7%) | 0.125 |
Yes | 15 (21.7%) | 20 (14.8%) | 37 (22.3%) | 17 (29.3%) | |
Immunosuppression* | |||||
No | 61 (88.4%) | 79 (58.5%) | 95 (57.2%) | 41 (70.7%) | <0.001 |
Yes | 8 (11.6%) | 56 (41.5%) | 71 (42.8%) | 17 (29.3%) | |
Obesity | |||||
No | 59 (85.5%) | 108 (80.0%) | 137 (82.5%) | 40 (69.0%) | 0.092 |
Yes | 10 (14.5%) | 27 (20.0%) | 29 (17.5%) | 18 (31.0%) | |
Diabetes | |||||
No | 50 (72.5%) | 116 (85.9%) | 144 (86.7%) | 42 (72.4%) | 0.008 |
Yes | 19 (27.5%) | 19 (14.1%) | 22 (13.3%) | 16 (27.6%) | |
Hepatic disease | |||||
No | 68 (98.6%) | 131 (97.0%) | 157 (94.6%) | 54 (93.1%) | 0.325 |
Yes | 1 (1.4%) | 4 (3.0%) | 9 (5.4%) | 4 (6.9%) | |
Hemoglobinopathy | |||||
No | 67 (97.1%) | 133 (98.5%) | 162 (97.6%) | 58 (100%) | 0.598 |
Yes | 2 (2.9%) | 2 (1.5%) | 4 (2.4%) | 0 (0%) | |
Neurological disease | |||||
No | 65 (94.2%) | 110 (81.5%) | 146 (88.0%) | 54 (93.1%) | 0.029 |
Yes | 4 (5.8%) | 25 (18.5%) | 20 (12.0%) | 4 (6.9%) | |
Number of comorbidities | |||||
median [Q1, Q3] | 2.00 [1.00, 3.00] | 1.00 [1.00, 2.00] | 1.00 [1.00, 2.00] | 2.00 [1.00, 3.00] | 0.003 |
min-max | 0-4.00 | 0-5.00 | 0-4.00 | 0-4.00 | |